Indivior (INDV) Investor presentation summary

Leadership in opioid use disorder (OUD) treatment

• Over 20 years of experience in OUD treatment, with more than 475,000 patients treated.

• SUBLOCADE is the leading monthly long-acting injectable (LAI) for moderate to severe OUD.

• Achieved $1.2B in revenue in 2025, reflecting a strong financial position.

Strategic focus and operational execution

• Sharpened focus on U.S. SUBLOCADE as the highest growth opportunity.

• Implemented a new operating model to drive bottom-line growth and cash flow.

• Simplified organization and completed Phase I of the Action Agenda, setting the stage for accelerated growth.

Financial performance and guidance

• FY 2025 SUBLOCADE net revenue grew 13% to $856m; adjusted EBITDA rose 20% to $428m.

• Adjusted EBITDA margin increased to 35% in 2025, up 5 percentage points year-over-year.

• 2026 guidance: total net revenue $1,125m–$1,195m, SUBLOCADE net revenue $905m–$945m, adjusted EBITDA $535m–$575m.

• Non-GAAP operating expenses expected to decrease by 29% in 2026, not exceeding $450m.